Therapy News and Research

RSS

Crucial link between protein synthesis and autism spectrum disorders

Researchers from McGill University and the University of Montreal have identified a crucial link between protein synthesis and autism spectrum disorders (ASD), which can bolster new therapeutic avenues.

22 Nov 2012

Somnogen induces sleep in patients with primary hypersomnia

Researchers at Emory University School of Medicine have discovered that dozens of adults with an elevated need for sleep have a substance in their cerebrospinal fluid that acts like a sleeping pill.

22 Nov 2012

Citicoline not superior to placebo in treating traumatic brain injury

Although approved for use for treating traumatic brain injury (TBI) in nearly 60 countries, use of citicoline in a randomized trial that included more than 1,200 participants with TBI did not result in improvement in functional and cognitive status, according to a study appearing in the November 21 issue of JAMA.

22 Nov 2012

Study demonstrates memory-enhancing effects of low-level light therapy

It's called the "Silver Tsunami" - the swelling number of baby boomers surpassing age 65. As medical advancements extend their lives, they're expected to live well into their 80s and 90s - outlasting any generation in American history.

22 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

Australian TGA approves Genzyme’s AUBAGIO to treat relapsing forms of multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

21 Nov 2012

Watch-and-wait approach feasible following adjuvant therapy for rectal cancer

Patients with rectal cancer managed conservatively following a complete response to chemoradiotherapy achieve similar rates of disease control as those who undergo rectal resection, research shows.

21 Nov 2012

Exercise relieves cancer fatigue

A review of studies spanning 45 years shows that exercise, particularly aerobic rather than strength- or flexibility-based training, improves fatigue in cancer patients.

21 Nov 2012

Symptomatic voice therapy enhances vocal exercise response in transgender patients

Vocal function exercises do not significantly improve the voice feminization of male-to-female transgender patients, but researchers say that symptomatic voice therapy and the experience of full-time living as a woman may help.

21 Nov 2012

Computational apolipoprotein estimates ‘reliable’ for CV risk

Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.

21 Nov 2012

Rituximab may help patients with aPL-related clinical problems

Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.

21 Nov 2012

Panel backs routine HIV screenings for teens, adults

The U.S. Preventive Services Task Force advises that nearly everyone ages 15 to 64 should be screened for the HIV virus, a recommendation which, if adopted, would require Medicare and most private health insurers to pay for the tests.

21 Nov 2012

Discovery of DKK1-WNT pathway reveals new drug targets for Alzheimer's

The discovery of the molecular pathway that drives the changes seen in the brains of Alzheimer's patients is reported today, revealing new targets for drug discovery that could be exploited to combat the disease. The study gives the most detailed understanding yet of the complex processes leading to Alzheimer's.

21 Nov 2012

New polymer nanoparticles can generate heat and kill colorectal cancer cells

Researchers at Wake Forest Baptist Medical Center have modified electrically-conductive polymers, commonly used in solar energy applications, to develop revolutionary polymer nanoparticles (PNs) for a medical application. When the nanoparticles are exposed to infrared light, they generate heat that can be used to kill colorectal cancer cells.

21 Nov 2012

Scientists uncover new role for TLR4 in development of tissue fibrosis or scarring

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

21 Nov 2012

Simple, accurate testing protocol to determine driving fitness in individuals with MS

A simple, accurate testing protocol to determine driving fitness in individuals with multiple sclerosis is the aim of a three-year study at Georgia Health Sciences University.

21 Nov 2012

Acetylon's ective histone deacetylase inhibitors to be showcased at 54th ASH annual meeting

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced that its selective histone deacetylase (HDAC) inhibitors will be featured in five posters and one oral presentation at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place December 8-11, 2012, in Atlanta, Georgia.

21 Nov 2012

Sharp decline in ECT availability and use in the U.S. general hospitals

Electroconvulsive therapy (ECT) is considered the most effective treatment option for patients with severe depression who cannot find symptom relief through antidepressant medications or psychotherapy. In a new study, researchers at Butler Hospital and Bradley Hospital in Rhode Island found a sharp decline in the availability and use of ECT in general hospitals across the U.S.

21 Nov 2012

Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology.

From Thermo Fisher Scientific Inc. 21 Nov 2012

Musical tones can reset the brain and effectively reduce insomnia

If you are among the 50 percent of Americans who suffer from insomnia, then you have probably tried everything – from warm milk to melatonin pills or prescription medications to induce sleep – with varying degrees of success and side effects. But what if sleep could be achieved not by a substance, but through 'balancing' brain activity?

21 Nov 2012